**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 85614

**Manuscript Type:** MINIREVIEWS

**Research progress on drug delivery systems for curcumin in the treatment of gastrointestinal tumors**

Wu X *et al*. Curcumin in gastrointestinal tumors

Xin Wu, Yang Yang

**Xin Wu,** Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China

**Yang Yang,** Department of Respiratory Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China

**Author contributions:** Wu X and Yang Y contributed equally to the conception, design, and literature search; Wu X drafted the manuscript and prepared the table and figure; Yang Y modified and revised the manuscript.

**Corresponding author: Yang Yang, MM, Associate Professor,** Department of Respiratory Oncology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, Heilongjiang Province, China.78100178@qq.com

**Received:** May 11, 2023

**Revised:** June 11, 2023

**Accepted:** July 11, 2023

**Published online:**

**Abstract**

Curcumin is a natural compound with a diketone structure, which can control the growth, metastasis, recurrence, neovascularization, invasion, and drug resistance of gastrointestinal tumors by inhibiting nuclear factor κB, overexpression of tumor cells, vascular endothelial growth factor, *etc*. However, due to the low bioavailability of curcumin formulation, it did not fully exert its pharmacological effects, and its application and development in the treatment of various malignant tumors are still limited. This review summarizes the research on drug delivery systems of curcumin combating digestive tract tumors in order to further reduce the toxic side effects of curcumin-containing drugs and fully exert their pharmacological activities, and improve their bioavailability and clinical value.

**Key Words:** Curcumin; Digestive tract tumors; Delivery system; Water-soluble; Solubility

Wu X, Yang Y. Research progress on drug delivery systems for curcumin in the treatment of gastrointestinal tumors. *World J Gastrointest Oncol* 2023; In press

**Core Tip:** Curcumin can control the growth, metastasis, recurrence, neovascularization, invasion, and drug resistance of gastrointestinal tumors by inhibiting nuclear factor κB, overexpression of tumor cells, and vascular endothelial growth factor. It is important to clarify the application value of curcumin by different drug delivery systems to optimize the treatment of gastrointestinal tumors.

**INTRODUCTION**

As the detection rate of advanced gastrointestinal tumors continues to rise, combination chemotherapy regimens, such as paclitaxel, capecitabine, and cisplatin, have become necessary to prolong patient survival[1,2]. However, many chemotherapy drugs have poor tumor selectivity and often have severe toxic side effects, which can damage the immune system's defense and regulatory functions and even make patients unable to tolerate subsequent treatments or develop drug resistance[3,4]. Moreover, the cost of chemotherapy combined with molecular targeted therapy is high, and patients have a low acceptance rate, making it unsuitable for widespread clinical use[5]. Compared with conventional chemotherapy and targeted therapy, curcumin biological formulations not only have low cost and high safety but also have anti-cancer, anti-virus, immune and inflammation regulation, and anti-cardiovascular fibrosis characteristics. Curcumin has therapeutic value in a variety of diseases such as esophageal cancer, gastric cancer, pancreatic cancer, biliary tract disease, rheumatic disease, and psoriasis[6,7]. However, as curcumin has poor water solubility, unstable properties under neutral and alkaline pH conditions, and strong photo-degradation, its pharmacological effects have not been well exerted[8,9]. Therefore, to develop a more scientific and efficient curcumin drug formulation, we performed a detailed analysis of the drug delivery systems for curcumin to increase its bioavailability and enhance its effectiveness against gastrointestinal tumors (Table 1, Figure 1).

**CURCUMIN DRUG DELIVERY SYSTEMS**

***Polymer***

Micelles polymer micelles are a thermodynamically stable colloidal solution with a shell-core structure. The core can carry hydrophobic drugs and effectively reduce the degradation loss of drugs, enhance the drug permeability and retention, and thus increase the concentration of drugs in the target site or accumulate the drugs in specific areas, thereby strengthening their killing effect on tumor cells and significantly reducing the toxic side effects on normal cells and tissues[10,11]. Compared with traditional drug delivery systems, curcumin micelles can not only improve the uptake rate of drugs by tumor cells but also select appropriate micelles based on the specific conditions and related symptoms of tumor patients, such as bioadhesive micelles, active targeting micelles, pH-sensitive micelles, and reversal of multidrug-resistant micelles[12]. In immunotherapy of osteosarcoma, Jin *et al*[13] found that dichloroacetic acid mitochondrial-targeted polymer micelles could induce cell apoptosis by initiating the mitochondrial oxidative stress response, enhancing immunity, and inhibiting the tumor microenvironment. In addition, by designing the hydrophobic core of polymer micelles and the hydrophobic membrane of the vesicles, the shell-core structure becomes a photocatalyst, which can effectively avoid the attack of photodynamic oxygen on enzymatic substances, keep the enzyme in an active state, and thus enhance the biocompatibility and activity of the delivery system[14]. It should be noted that comprehensive tests on encapsulation efficiency, particle size, drug loading, and drug release rate within 48 h are required to prepare curcumin polymer micelles to the fullest extent possible to overcome its poor water solubility and maximize its anti-tumor effects.

***Liposome***

Liposomes are lipid bilayer microvesicle carriers that can encapsulate multiple drugs and have good targeting and lymphatic directionality. Compared with ordinary carriers, they can not only delay renal metabolism, reduce drug toxicity but also serve as passive targeted drugs for the reticuloendothelial system, thus protecting the liver and improving drug efficacy[15]. In a mouse experiment, Li *et al*[16] compared several different curcumin drug delivery systems and found that mice given curcumin liposomes had greater improvements in hepatic steatosis than control group mice or mice given curcumin suspensions, and smaller abdominal adipocytes. In the study of digestive tract tumors, curcumin analogs, unlike non-steroidal anti-inflammatory drugs, have important value in regulating the cancer gene pathway, and cause fewer adverse reactions such as mucosal bleeding and gastrointestinal ulcers[17]. When curcumin acts on gastric or colorectal cancer, it can regulate the cell's anti-inflammatory, anti-cell apoptosis and antioxidant mechanisms through signal pathways such as DNA methylation, nuclear factor-erythroid 2-related factor 2, and histone modification, thus regulating the transcription of factors, such as heme oxygenase-1, Bcl-2, Bcl-xL, delaying tumor progression, and achieving multi-organ protection[18,19].

***Microsphere***

Microspheres, also known as microcapsules, are miniature spherical capsules made of polymeric materials that encapsulate or adsorb solid or liquid drugs. Their outer shell can mask the unpleasant odor of drugs, prevent contraindications in complex formulations, and reduce the stimulatory effects of chemotherapy drugs on the gastrointestinal mucosa[20]. The most commonly used microencapsulation method in clinical practice is to develop sustained-release and targeted drugs to control disease progression or symptoms. Some microspheres can also embed live cells and biologically active blood substances to prevent them from denaturing or becoming ineffective[21]. Researchers extracted proteins from lotus seeds and used them to encapsulate curcumin[22]. They found that at a concentration of 50mg/mL, the encapsulation rate of curcumin was 86.32%. After digestion in the gastrointestinal tract, the cumulative release rate of curcumin-LSP was 64.3%, while that of curcumin-LSP-pectin particles was 72.4%. Moreover, the dissolution rate of curcumin-LSP-pectin particles was relatively higher. Thus, microencapsulated compounds have a higher application value.

***Nanoparticle***

Nanoparticles (NPs) can penetrate into membrane cells, spread along nerve synapses and lymphatic vessels, and selectively accumulate in different cells and some cell structures[23]. According to their different shell-core structures and materials, NPs are divided into multiple drug delivery systems, such as lipophilic NPs, nanocapsules, nanospheres, and inorganic NPs. Their carriers can be hydrophobic or hydrophilic compounds, as well as small molecules, biomacromolecules, proteins, and vaccines[24]. Moreover, by adjusting the composition, stability, reactivity, and surface charge of NPs and carriers, the loading effect and release kinetics of drugs can be precisely controlled[25]. Lushchak *et al*[26] pointed out that nanoparticles carrying various plant bioactive compounds had a longer half-life than traditional formulations and could improve the permeability of epithelial cells and delayed cellular aging. Nabila *et al*[27] used nanolipid technology to prepare nano-curcumin and compared it with curcumin solution, proving that nano-curcumin had greater antiviral potential. It is worth noting that inorganic NPs synthesized from materials, such as gold, iron oxide, and silicon dioxide, have unique value in diagnosis, arterial imaging, photothermal therapy, and sonodynamic therapy. However, due to their toxicity and low solubility, the clinical application of such NPs still has certain limitations[28]. Dutta *et al*[29] coated the anionic surfactant sodium dodecyl sulfate (SDS) on the surface of hydrophobic Fe3O4 (oleic acid modified) nanoparticles to prepare a surface-active agent-stabilized, highly water-dispersible Fe3O4 magnetic nanocarrier (SMNC) capable of simultaneously carrying hydrophobic and hydrophilic anticancer drugs. Doxorubicin is adsorbed onto the surface of the nanocarrier by electrostatic interactions, while curcumin is encapsulated in the hydrophobic intermediate layer between oleic acid and SDS. The drug carrier has high drug loading capacity, good sustained release performance, and good cellular uptake ability. In addition, the drug carrier exhibits excellent heating ability under an alternating magnetic field and can be used as an effective heat source for hyperthermia.

***Nanogel***

Nanogel is a type of intramolecular cross-linked polymer with a particle size generally within 1000 nm. It has an internal network structure and can be dispersed into nanoscale hydrogel particles in aqueous solutions[30]. It can also be used as anti-fouling and antibacterial surface coatings, reducing the adhesion of bacteria and viruses on medical materials. The pH in the normal physiological environment of the body differs significantly from that outside the tumor cells, resulting in a significant redox potential difference between the inside and outside of the cells. However, monodispersed nanoscale hydrogels can respond specifically and accurately to the pH and redox potential differences between tumor tissues and normal tissues, creating conditions for targeted delivery of drugs to cancer sites[31,32]. Chemotherapy combined with immunotherapy is currently a popular method for treating mid-to-late-stage tumors. Its main goal is to promote the death of immunogenic cells, activate the powerful function of the immune system, and achieve the purpose of inhibiting tumor growth and improving the immunosuppressive tumor microenvironment[33]. Ma *et al*[34] prepared mannitol nanogels based on polyβ-amino esters to treat breast cancer and found that it could overcome the limitations of immunotherapy. Therefore, nanogels can achieve specific co-delivery of tumor drugs.

***Cyclodextrin***

Cyclodextrin is a cyclical oligosaccharide derived from starch. By appropriately modifying it chemically, amorphous or partially crystalline derivatives such as α-cyclodextrin, β-cyclodextrin, partially methylated-β-cyclodextrin, *etc.*, can be formed, which can significantly improve its water solubility and greatly reduce its gastrointestinal toxicity[35]. Among them, the inclusion complex of hydroxypropyl-β-cyclodextrin and curcumin has not only a high inclusion rate and high solubility, but also a 2.8-fold increase in bioavailability compared to ordinary curcumin preparations, and the concentration in the brain increases by 38.7-fold, showing a significant antiepileptic effect[36]. In addition, Chen *et al*[37] showed that curcumin-cyclodextrin complex has a protective effect on H2O2-induced LO2 cell damage, can effectively inhibit the overexpression of caspase-3, and alleviate liver, kidney, brain and skeletal muscle damage. This indicates that preparing curcumin-cyclodextrin inclusion complexes according to the chemical and biological properties of drugs can alleviate liver, kidney, and nerve toxicities during anti-tumor chemotherapy. In the study of curcumin solubility, the antioxidant activity of curcumin inclusion complexes formed with β-cyclodextrin and polyvinylpyrrolidone (PVP) was (96.02 ± 2.46)%, while the antioxidant activity of pure curcumin was only (58.02 ± 2.21)%. This shows that designing curcumin-β-cyclodextrin complexes with PVP can further improve the *in vivo* activity of curcumin[38].

**CLINICAL RESEACH PROGRESS**

Developing drug delivery systems for curcumin, such as micelles, complexes, solvent-free pH-driven capsules, and gels, to fully enhance its effectiveness and develop therapeutic or functional products, has become one of the choices to promote overall health and increase tumor remission rates[39]. However, despite the current clinical research in gastrointestinal tumors, the efficacy of curcumin remains uncertain (Table 2)[40-43]. In addition to the studies shown in the table, Hipólito-Reis *et al*[44] demonstrated that by reducing the release and production of inflammatory mediators using curcumin, curcumin can lower cell proliferation, blood vessel growth, invasion, and adhesion, or regulate cell apoptosis, lipid metabolism mechanisms, *etc.*, which can effectively improve the occurrence and development of endometriosis and achieve long-term control or clinical cure[45,46]. Meanwhile, the invasion and proliferation of tumor cells can also promote the secretion of multifunctional chemokines such as TNF-α, IL-6, IL-8, IL-10, decrease pain thresholds, and promote inflammatory exudation and necrosis of local lesions. Therefore, Nanavati *et al*[47] believe that supplementing 90-5000 mg curcumin daily can effectively improve subjective pain perception and increase the body's antioxidant capacity.

**CONCLUSION**

The anti-tumor effect of curcumin is closely related to multiple mechanisms. When it acts on the signaling pathway of various cytokines, it can exert different regulatory functions, thereby regulating immunity and inflammation, protecting cells, and inhibiting tumor growth. For specific cancer patients, the development of curcumin delivery systems can significantly enhance the targeting and long-circulating effects of the drugs. Polymer micelles, liposomes, and microspheres have considerable advantages, but this article did not provide a detailed analysis of their drawbacks, and it is not entirely clear how to choose the material and type of drug delivery systems. Therefore, in future research, the application value of curcumin by different drug delivery systems needs to be further analyzed to optimize the treatment of gastrointestinal tumors.

**REFERENCES**

1 **Santa Chalarca CF**, Dalal RJ, Chapa A, Hanson MG, Reineke TM. Cation Bulk and pK(a) Modulate Diblock Polymer Micelle Binding to pDNA. *ACS Macro Lett* 2022; **11**: 588-594 [PMID: 35575319 DOI: 10.1021/acsmacrolett.2c00015]

2 **Tulsi R**, Ul Haque MM, Hanif FM, Devi A, Mubarak M, Hassan Luck N. Metastasis of Duodenal Adenocarcinoma to the Urinary Bladder Presenting as Hematuria. *J Transl Int Med* 2021; **9**: 143-145 [PMID: 34497753 DOI: 10.2478/jtim-2021-0010]

3 **Chao YH**, Gao MM, Nie AZ, Sun BJ, Du SZ, Nie HJ. Development of disulfide bond mediated tumor microenvironment responsive drug delivery system. *Zhongnan Yaoxue* 2021; **7**: 1364-1369

4 **Liu P**, Zhu H, Zhu H, Zhang X, Feng A, Zhu X, Sun Y. Predicting Survival for Hepatic Arterial Infusion Chemotherapy of Unresectable Colorectal Liver Metastases: Radiomics Analysis of Pretreatment Computed Tomography. *J Transl Int Med* 2022; **10**: 56-64 [PMID: 35702189 DOI: 10.2478/jtim-2022-0004]

5 **Angeline N**, Suhito IR, Kim CH, Hong GP, Park CG, Bhang SH, Luo Z, Kim TH. A fibronectin-coated gold nanostructure composite for electrochemical detection of effects of curcumin-carrying nanoliposomes on human stomach cancer cells. *Analyst* 2020; **145**: 675-684 [PMID: 31803868 DOI: 10.1039/c9an01553a]

6 **Calibasi-Kocal G**, Pakdemirli A, Bayrak S, Ozupek NM, Sever T, Basbinar Y, Ellidokuz H, Yigitbasi T. Curcumin effects on cell proliferation, angiogenesis and metastasis in colorectal cancer. *J BUON* 2019; **24**: 1482-1487 [PMID: 31646795 DOI: 10.36472/msd.v7i4.368]

7 **Chen ZR**, Fan B. Research progress on the mechanism and local delivery system of curcumin in the treatment of psoriasis. *Shijie Linchuang Yaowu* 2022; **43**: 1207-1213

8 **Mollazadeh H**, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: The role of interleukin-10. *Crit Rev Food Sci Nutr* 2019; **59**: 89-101 [PMID: 28799796 DOI: 10.1080/10408398.2017.1358139]

9 **Zhang XL**, Li YP, Lv SW, Wang YH, Li YJ. Research Progress of Curcumin Nanocarriers and Their Applications. *Dangdai Huagong* 2021; **11**: 2685-2688

10 **Liu YR**, Wu MF, Sun YQ. Preparation and Evaluation of Curcumin-loaded Polymeric Micelles Based on Copolymer Cholesterol-hyaluronic Acid. *Zhongguo Yaoxue Zazhi* 2020; **51**: 613-619

11 **Yusuf H**, Wijiani N, Rahmawati RA, Primaharinastiti R, Rijal MAS, Isadiartuti D. Analytical method for the determination of curcumin entrapped in polymeric micellar powder using HPLC. *J Basic Clin Physiol Pharmacol* 2021; **32**: 867-873 [PMID: 34214361 DOI: 10.1515/jbcpp-2020-0491]

12 **Mizumoto A**, Ohashi S, Kamada M, Saito T, Nakai Y, Baba K, Hirohashi K, Mitani Y, Kikuchi O, Matsubara J, Yamada A, Takahashi T, Lee H, Okuno Y, Kanai M, Muto M. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. *J Gastroenterol* 2019; **54**: 687-698 [PMID: 30737573 DOI: 10.1007/s00535-019-01549-x]

13 **Jin J**, Yuan P, Yu W, Lin J, Xu A, Xu X, Lou J, Yu T, Qian C, Liu B, Song J, Li L, Piao Y, Xie T, Shen Y, Tao H, Tang J. Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy. *ACS Nano* 2022; **16**: 10327-10340 [PMID: 35737477 DOI: 10.1021/acsnano.2c00192]

14 **Zhang N**, Trépout S, Chen H, Li MH. AIE Polymer Micelle/Vesicle Photocatalysts Combined with Native Enzymes for Aerobic Photobiocatalysis. *J Am Chem Soc* 2023; **145**: 288-299 [PMID: 36562998 DOI: 10.1021/jacs.2c09933]

15 **Patel SS**, Acharya A, Ray RS, Agrawal R, Raghuwanshi R, Jain P. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. *Crit Rev Food Sci Nutr* 2020; **60**: 887-939 [PMID: 30632782 DOI: 10.1080/10408398.2018.1552244]

16 **Li H**, Liu ZH, Li H, Qing DX. Effect of curcumin liposomes on lipid-lowering and hepatoprotective effects of hyperlipidemia-induced nonalcoholic fatty liver disease mice]. *Chin Med* 2020; **15**: 1053-1057

17 **Morshedi K**, Borran S, Ebrahimi MS, Masoud Khooy MJ, Seyedi ZS, Amiri A, Abbasi-Kolli M, Fallah M, Khan H, Sahebkar A, Mirzaei H. Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review. *Phytother Res* 2021; **35**: 4834-4897 [PMID: 34173992 DOI: 10.1002/ptr.7119]

18 **Zhang W**, Cui N, Ye J, Yang B, Sun Y, Kuang H. Curcumin's prevention of inflammation-driven early gastric cancer and its molecular mechanism. *Chin Herb Med* 2022; **14**: 244-253 [PMID: 36117672 DOI: 10.1016/j.chmed.2021.11.003]

19 **Wu R**, Wang L, Yin R, Hudlikar R, Li S, Kuo HD, Peter R, Sargsyan D, Guo Y, Liu X, Kong AN. Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer. *Mol Carcinog* 2020; **59**: 227-236 [PMID: 31820492 DOI: 10.1002/mc.23146]

20 **Joshi P**, Joshi S, Semwal D, Bisht A, Paliwal S, Dwivedi J, Sharma S. Curcumin: An Insight into Molecular Pathways Involved in Anticancer Activity. *Mini Rev Med Chem* 2021; **21**: 2420-2457 [PMID: 33480345 DOI: 10.2174/1389557521666210122153823]

21 **Patel SS**, Pushpadass HA, Franklin MEE, Battula SN, Vellingiri P. Microencapsulation of curcumin by spray drying: Characterization and fortification of milk. *J Food Sci Technol* 2022; **59**: 1326-1340 [PMID: 35250058 DOI: 10.1007/s13197-021-05142-0]

22 **Su Y**, Chen Y, Zhang L, Adhikari B, Xu B, Li J, Zheng T. Synthesis and characterization of lotus seed protein-based curcumin microcapsules with enhanced solubility, stability, and sustained release. *J Sci Food Agric* 2022; **102**: 2220-2231 [PMID: 34611905 DOI: 10.1002/jsfa.11560]

23 **Asadi S**, Gholami MS, Siassi F, Qorbani M, Sotoudeh G. Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. *Phytother Res* 2020; **34**: 896-903 [PMID: 31788880 DOI: 10.1002/ptr.6571]

24 **Wu Y**, Liu H, Li Z, Huang D, Nong L, Ning Z, Hu Z, Xu C, Yan JK. Pectin-decorated selenium nanoparticles as a nanocarrier of curcumin to achieve enhanced physicochemical and biological properties. *IET Nanobiotechnol* 2019; **13**: 880-886 [PMID: 31625531 DOI: 10.1049/iet-nbt.2019.0144]

25 **Li YQ**, Li XJ. Basic and clinical research progress in antitumor effect of curcumin. *Zhongguo Yaolixue Yu Dulixue Zazhi* 2020; **34**: 321-335

26 **Lushchak O**, Strilbytska O, Koliada A, Zayachkivska A, Burdyliuk N, Yurkevych I, Storey KB, Vaiserman A. Nanodelivery of phytobioactive compounds for treating aging-associated disorders. *Geroscience* 2020; **42**: 117-139 [PMID: 31686375 DOI: 10.1007/s11357-019-00116-9]

27 **Nabila N**, Suada NK, Denis D, Yohan B, Adi AC, Veterini AS, Anindya AL, Sasmono RT, Rachmawati H. Antiviral Action of Curcumin Encapsulated in Nanoemulsion against Four Serotypes of Dengue Virus. *Pharm Nanotechnol* 2020; **8**: 54-62 [PMID: 31858909 DOI: 10.2174/2211738507666191210163408]

28 **Dai T**, He W, Yao C, Ma X, Ren W, Mai Y, Wu A. Applications of inorganic nanoparticles in the diagnosis and therapy of atherosclerosis. *Biomater Sci* 2020; **8**: 3784-3799 [PMID: 32469010 DOI: 10.1039/d0bm00196a]

29 **Dutta B**, Shetake NG, Barick BK, Barick KC, Pandey BN, Priyadarsini KI, Hassan PA. pH sensitive surfactant-stabilized Fe(3)O(4) magnetic nanocarriers for dual drug delivery. *Colloids Surf B Biointerfaces* 2018; **162**: 163-171 [PMID: 29190467 DOI: 10.1016/j.colsurfb.2017.11.054]

30 **Guo XY**, Wang Z, Xia MP. [Research progress of medical nano gel surface coating with antifouling/antibacterial function]. *Mater Introduct* 2022; **36**: 446-451

31 **Maleki Dizaj S**, Alipour M, Dalir Abdolahinia E, Ahmadian E, Eftekhari A, Forouhandeh H, Rahbar Saadat Y, Sharifi S, Zununi Vahed S. Curcumin nanoformulations: Beneficial nanomedicine against cancer. *Phytother Res* 2022; **36**: 1156-1181 [PMID: 35129230 DOI: 10.1002/ptr.7389]

32 **Zakaria H**, El Kurdi R, Patra D. A Novel Study on the Self-Assembly Behavior of Poly(lactic-co-glycolic acid) Polymer Probed by Curcumin Fluorescence. *ACS Omega* 2022; **7**: 9551-9558 [PMID: 35350334 DOI: 10.1021/acsomega.1c06919]

33 **Lu Y**, Jia D, Ma X, Liang M, Hou S, Qiu W, Gao Y, Xue P, Kang Y, Xu Z. Reduction-Responsive Chemo-Capsule-Based Prodrug Nanogel for Synergistic Treatment of Tumor Chemotherapy. *ACS Appl Mater Interfaces* 2021; **13**: 8940-8951 [PMID: 33565847 DOI: 10.1021/acsami.0c21710]

34 **Ma X**, Yang S, Zhang T, Wang S, Yang Q, Xiao Y, Shi X, Xue P, Kang Y, Liu G, Sun ZJ, Xu Z. Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy. *Acta Pharm Sin B* 2022; **12**: 451-466 [PMID: 35127398 DOI: 10.1016/j.apsb.2021.05.016]

35 **Isadiartuti D**, Rosita N, Ekowati J, Syahrani A, Ariyani T, Rifqi MA. The thermodynamic study of p-methoxycinnamic acid inclusion complex formation, using β-cyclodextrin and hydroxypropyl-β-cyclodextrin. *J Basic Clin Physiol Pharmacol* 2021; **32**: 663-667 [PMID: 34214343 DOI: 10.1515/jbcpp-2021-0008]

36 **Zeng Y**, Lv Y, Hu M, Guo F, Zhang C. Curcumin-loaded hydroxypropyl-β-cyclodextrin inclusion complex with enhanced dissolution and oral bioavailability for epilepsy treatment. *Xenobiotica* 2022; **52**: 718-728 [PMID: 36227237 DOI: 10.1080/00498254.2022.2136044]

37 **Chen J**, Li J, Fan T, Zhong S, Qin X, Li R, Gao J, Liang Y. Protective effects of curcumin/cyclodextrin polymer inclusion complex against hydrogen peroxide-induced LO2 cells damage. *Food Sci Nutr* 2022; **10**: 1649-1656 [PMID: 35592280 DOI: 10.1002/fsn3.2787]

38 **Jafar M**, Khalid MS, Aldossari MFE, Amir M, Alshaer FI, Adrees FAA, Gilani SJ, Alshehri S, Hassan MZ, Imam SS. Formulation of Curcumin-β-cyclodextrin-polyvinylpyrrolidone supramolecular inclusion complex: experimental, molecular docking, and preclinical anti-inflammatory assessment. *Drug Dev Ind Pharm* 2020; **46**: 1524-1534 [PMID: 32808552 DOI: 10.1080/03639045.2020.1810268]

39 **Abd El-Hack ME**, El-Saadony MT, Swelum AA, Arif M, Abo Ghanima MM, Shukry M, Noreldin A, Taha AE, El-Tarabily KA. Curcumin, the active substance of turmeric: its effects on health and ways to improve its bioavailability. *J Sci Food Agric* 2021; **101**: 5747-5762 [PMID: 34143894 DOI: 10.1002/jsfa.11372]

40 **Gunther JR**, Chadha AS, Guha S, Raju GS, Maru DM, Munsell MF, Jiang Y, Yang P, Felix E, Clemons M, Mathew GG, Singh PK, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Delclos ME, Crane CH, Das P, Krishnan S. A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer. *J Gastrointest Oncol* 2022; **13**: 2938-2950 [PMID: 36636059 DOI: 10.21037/jgo-22-259]

41 **Wang WB**, Zhang LX, Luo Q, Ren HY, Niu SR. Curcumin reverses the drug resistance of esophageal cancer Eca-109 /VCR cells. *Zhongguo Linchuang Yaolixue Zazhi* 2021; **37**: 136-139

42 **Howells LM**, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z, Griffin-Teall N, Singh R, Foreman N, Patel SR, Morgan B, Steward WP, Gescher A, Thomas AL, Brown K. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. *J Nutr* 2019; **149**: 1133-1139 [PMID: 31132111 DOI: 10.1093/jn/nxz029]

43 **Yang WL**, Yang RP, Luo YS, Hu S, Liu Q. Clinical analysis of curcumin combined with FOLFOX regimen in the treatment of advanced gastric cancer. I*nner Mongolia Yike Daxue Xuebao* 2019; **41**: 96-99

44 **Hipólito-Reis M**, Neto AC, Neves D. Impact of curcumin, quercetin, or resveratrol on the pathophysiology of endometriosis: A systematic review. *Phytother Res* 2022; **36**: 2416-2433 [PMID: 35583746 DOI: 10.1002/ptr.7464]

45 **Ms SAB**, Waldman PhD HS, Krings PhD BM, Lamberth PhD J, Smith PhD JW, McAllister PhD MJ. Effect of Curcumin Supplementation on Exercise-Induced Oxidative Stress, Inflammation, Muscle Damage, and Muscle Soreness. *J Diet Suppl* 2020; **17**: 401-414 [PMID: 31025894 DOI: 10.1080/19390211.2019.1604604]

46 **Wang Q**, Zhang K, Weng W, Chen L, Wei C, Bao R, Adu-Frimpong M, Cao X, Yu Q, Shi F, Toreniyazov E, Ji H, Xu X, Yu J. Liquiritin-Hydroxypropyl-Beta-Cyclodextrin Inclusion Complex: Preparation, Characterization, Bioavailability and Antitumor Activity Evaluation. *J Pharm Sci* 2022; **111**: 2083-2092 [PMID: 35367247 DOI: 10.1016/j.xphs.2022.03.021]

47 **Nanavati K**, Rutherfurd-Markwick K, Lee SJ, Bishop NC, Ali A. Effect of curcumin supplementation on exercise-induced muscle damage: a narrative review. *Eur J Nutr* 2022; **61**: 3835-3855 [PMID: 35831667 DOI: 10.1007/s00394-022-02943-7]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 11, 2023

**First decision:** May 31, 2023

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Iruarrizaga-Lejarreta M, Spain; Sledzinski T, Poland **S-Editor:** Yan JP **L-Editor:** A **P-Editor:** Yan JP

**Figure Legends**

图示

描述已自动生成

**Figu****re 1** **Curcumin improvement through drug delivery systems.**

**T****able 1 Summary of drug delivery systems**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug delivery system** | **Structure** | **Advantage** | **Disadvantage** | **Common types** |
| Polymer | Shell-core structure | Hydrophobic, high and precise drug concentration with low side effects | Poor water solubility | Bioadhesive micelles, active targeting micelles, *etc*. |
| Liposome | Lipid bilayer microvesicle carriers | Diversity, targeting, lymphatic targeting, liver protection, etc | High cost | Unilamellar liposomes, multilamellar liposomes, liposome gel, *etc.* |
| Microsphere | Shell-core structure | Covering bad odors, avoiding incompatible combinations, high stability and safety | Relatively short duration and relatively large drug dosage | Conventional injection microspheres, occlusive microspheres, magnetic microspheres, *etc.* |
| Nanoparticle (NPs) | Shell-core structure | Amphiphilic, controllable loading effect, long half-life, *etc.* | Low solubility of inorganic NPs | Lipophilic NPs, nanocapsules, nanospheres, and inorganic NPs, *etc.* |
| Nanogel | Intramolecular cross-linked polymer | Anti-fouling, antibacterial, targeting, small size, easily penetrating cells, *etc.* | No obvious disadvantage | pH-responsive hydrogels, hyaluronic acid hydrogels, copolymer hydrogels |
| Cyclodextrin | Bimolecular complex | High water solubility, low toxicity, high stability | No obvious disadvantage | α-cyclodextrin, β-cyclodextrin, partially methylated-β-cyclodextrin, *etc.* |

**Table 2 Clinical study of** **c****urcumin effects on gastrointestinal tumors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer type** | **Study category** | **No.** | **Dosage regimen** | **Results** |
| Colorectal cancer[37] | Phase II, randomized double-blind study | 22 | Capecitabine 825 mg/m2, *Bid*; curcumin 4 g, *Bid* | Curcumin does not increase the remission rate of patients |
| Esophageal cancer[38] | Controlled trial | 1 | Group A: 20 µg/mL curcumin-containing culture; Group B: 2 µg/mL Vincristine-containing culture; Combined group: 20 µg/mL curcumin+2 µg/mL vincristine-containing culture | Curcumin reverses multidrug resistance of esophageal cancer cells |
| Metastatic colorectal cancer[39] | Phase IIa, randomized controlled trial | 28 | Control group: FOLFOX1; Research Group: FOLFOX + curcumin 2 g/d | Curcumin plus FOLFOX regimen significantly improves chemotherapy tolerance and safety |
| Advanced gastric cancer[40] | Randomized controlled trial | 56 | Control group: FOLFOX; Research Group: FOLFOX + curcumin 25 µmol/L, 1/d | Curcumin plus FOLFOX regimen significantly improves clinical remission rate and reduces toxic side effects |

1FOLFOX is a chemotherapy regimen consisting of oxaliplatin, leucovorin, and 5-fluorouracil. Taking FOLFOX4 as an example, on the first and second day, intravenous infusion of oxaliplatin 85 mg/m2 is administered for 2 h; intravenous infusion of leucovorin 200 mg/m2 for 2 h; and 5-fluorouracil is given at 400 mg/m2 as an initial intravenous bolus followed by a continuous infusion of 600 mg/m2 for 22 h. This medication regimen is repeated every 2 wk.